The Relationship of Mediterranean Diet Compliance with Metabolic Parameters, Obesity Markers and Inflammation in Women with Abdominal Obesity
DOI:
https://doi.org/10.5281/zenodo.17456072Keywords:
Abdominal obesity, Mediterranean diet, adropin, nesfatin-1Abstract
Aim: This study aimed to investigate the relationship between Mediterranean diet adherence and various metabolic, inflammatory and oxidative stress markers in women with and without abdominal obesity.
Materials and Methods: A total of 68 women aged 18–50 years participated in the study, including 34 women with abdominal obesity and 34 women without abdominal obesity. Anthropometric measurements, biochemical parameters and adherence to the Mediterranean Diet were assessed using the Mediterranean Diet Adherence Scale (MEDAS). Peptides, inflammatory markers and oxidative stress parameters were measured using the ELISA method.
Results: Women with abdominal obesity had significantly higher levels of insulin resistance (HOMA-IR), liver enzymes, C-reactive protein (CRP), tumor necrosis factor-alpha (TNF-α), interleukin-6 (IL-6) and an unfavorable lipid profile. They also had lower plasma antioxidant levels and MEDAS scores. Peptide analysis showed reduced levels of adropin, obestatin (OB), ghrelin (GH) and nesfatin-1, but an increased GH/OB ratio. A negative correlation was found between MEDAS scores and HOMA-IR, cholesterol, triglycerides and low-density lipoproteins (LDL). Positive correlations were observed between MEDAS scores and levels of adropin, obestatin and antioxidant parameters. TNF-α and IL-6 were negatively correlated with MEDAS scores.
Conclusion: Abdominal obesity in young women is associated with increased metabolic risk. Adherence to the Mediterranean diet has a protective role by reducing inflammation and oxidative stress, thus emphasizing its importance in dietary interventions aimed at metabolic health.
Downloads
References
1. Uzogara SG. Obesity epidemic, medical and quality of life consequences: A review. Int J Public Health Res. 2017;5(1):1.
2. De Lorenzo A, Gratteri S, Gualtieri P, Cammarano A, Bertucci P, Di Renzo L. Why primary obesity is a disease? J Transl Med. 2019;17(1):169.
3. World Health Organization. Obesity and Overweight [Internet]. Available from: https://www.who.int/news-room/fact-sheets/
detail/obesity-and-overweight [Accessed 25 Nov 2022].
4. Franco LP, Morais CC, Cominetti C. Normal-weight obesity syndrome: diagnosis, prevalence, and clinical implications. Nutr
Rev. 2016;74(9):558-70.
5. Turkish Endocrinology and Metabolism Society (TEMD). Obezite Tanı ve Tedavi Kılavuzu [Internet]. Available from: http://www.
temd.org.tr/admin/uploads/tbl_gruplar/20180525144116-2018-05-25tbl_gruplar144108.pdf [Accessed 25 Nov 2022].
6. Lemieux S. Contribution of visceral obesity to the insulin resistance syndrome. Can J Appl Physiol. 2001;26(3):273-90.
7. Hanefeld M. The metabolic syndrome: roots, myths and facts. Metab Syndr. 1997;13-24.
8. Sowers JR. Obesity as a cardiovascular risk factor. Am J Med. 2003;115(8):37-41.
9. Ezzati M, Riboli E. Can noncommunicable diseases be prevented? Lessons from studies of populations and individuals. Science.
2012;337(6101):1482-87.
10. Kimokoti RW, Millen BE. Nutrition for the prevention of chronic diseases. Med Clin North Am. 2016;100(6):1185-98.
11. Ali II, D’Souza C, Singh J, Adeghate E. Adropin’s role in energy homeostasis and metabolic disorders. Int J Mol Sci. 2022;23(15):8318.
12. Tuero C, Valenti V, Rotellar F, Landecho MF, Cienfuegos JA, Frühbeck G. Revisiting the ghrelin changes following bariatric
and metabolic surgery. Obes Surg. 2020;30(7):2763-80.
13. Nogueiras R, Pfluger P, Tovar S, et al. Effects of obestatin on energy balance and growth hormone secretion in rodents.
Endocrinology. 2007;148(1):21-6.
14. Tsuchiya T, Shimizu H, Yamada M, et al. Fasting concentrations of nesfatin‐1 are negatively correlated with body mass index in non‐obese males. Clin Endocrinol (Oxf ). 2010;73(4):484-90.
15. Martínez-González MÁ, Corella D, Salas-Salvadó J, et al. Cohort profile: design and methods of the PREDIMED study. Int J
Epidemiol. 2012;41(2):377-85.
16. Balcıoğlu H, Ünlüoğlu İ, Pehlivanoğlu EF. Akdeniz Diyeti Bağlılık Ölçeği’nin Türkçe’ye uyarlanması geçerlilik ve güvenilirliği.
Osmangazi Tıp Derg. 2019.
17. Magriplis E, Andreou E, Zampelas A. The Mediterranean Diet: What it is and its effect on abdominal obesity. In: Nutrition in
the Prevention and Treatment of Abdominal Obesity. Academic Press; 2019. p. 281-99.
18. Dinu M, Pagliai G, Lotti S, Giangrandi I, Colombini B, Sofi F. Adherence to Mediterranean Diet Measured through Medi-Lite Score and Obesity: A Retrospective Study. Nutrients. 2021;13(6):2007.
19. Bertoli S, Leone A, Vignati L, et al. Adherence to the Mediterranean diet is inversely associated with visceral abdominal tissue in Caucasian subjects. Clin Nutr. 2015;34(6):1266-72.
20. Babio N, Toledo E, Estruch R, et al. Mediterranean diets and metabolic syndrome status in the PREDIMED randomized trial.
CMAJ. 2014;186(17):E649-57.
21. Estruch R, Martínez-González MA, Corella D, et al. [Retracted] Effect of a high-fat Mediterranean diet on bodyweight and waist circumference: a prespecified secondary outcomes analysis of the PREDIMED randomised controlled trial. Lancet Diabetes Endocrinol. 2016;4(8):666-76.
22. Park YM, Zhang J, Steck SE, et al. Obesity mediates the association between Mediterranean diet consumption and insulin resistance
and inflammation in US adults. J Nutr. 2017;147(4):563-71.
23. Sangouni AA, Hassani Zadeh S, Mozaffari-Khosravi H, et al. Effect of Mediterranean diet on liver enzymes: a systematic review and meta-analysis of randomised controlled trials. Br J Nutr. 2022;128(7):1231-39.
24. Katsagoni CN, Georgoulis M, Papatheodoridis GV, et al. Effects of lifestyle interventions on clinical characteristics of patients with non-alcoholic fatty liver disease: A meta-analysis. Metabolism. 2017;68:119-32.
25. Moosavian SP, Arab A, Paknahad Z. The effect of a Mediterranean diet on metabolic parameters in patients with non-alcoholic fatty liver disease: A systematic review of randomized controlled trials. Clin Nutr ESPEN. 2020;35:40-6.
26. Chrysohoou C, Panagiotakos DB, Pitsavos C, et al. Adherence to the Mediterranean diet attenuates inflammation and coagulation process in healthy adults: The ATTICA Study. J Am Coll Cardiol. 2004;44(1):152-8.
27. St-Onge MP, Shechter A, Shlisky J, et al. Fasting plasma adropin concentrations correlate with fat consumption in human females. Obesity (Silver Spring). 2014;22(4):1056-63.
28. Stevens JR, Kearney ML, St-Onge MP, et al. Inverse association between carbohydrate consumption and plasma adropin concentrations in humans. Obesity (Silver Spring). 2016;24(8):1731-40.
29. Soltani S, Kolahdouz-Mohammadi R, Aydin S, et al. Circulating levels of adropin and overweight/obesity: a systematic review and meta-analysis of observational studies. Hormones (Athens). 2022;21(1):15-22.
30. Kuyumcu A, Kuyumcu MS, Ozbay MB, et al. Nesfatin-1: A novel regulatory peptide associated with acute myocardial infarction and Mediterranean diet. Peptides. 2019;114:10-6.
31. Garaulet M, Sánchez-Moreno C, Smith CE, et al. Ghrelin, sleep reduction and evening preference: relationships to CLOCK 3111 T/C SNP and weight loss. PLoS One. 2011;6(2):e17435.
32. Martínez-Lapiscina EH, Clavero P, Toledo E, et al. Mediterranean diet improves cognition: the PREDIMED-NAVARRA randomised trial. J Neurol Neurosurg Psychiatry. 2013;84(12):1318-1325.
33. İbrahim AS, Eldeeb MM, Salama OA, Rashad MM, Okasha KM. Possible association of ghrelin/obestatin balance with cardiometabolic risk in obese subjects with Helicobacter pylori. Endocr Regul. 2018;52(2):101-9.
34. Zhang JV, Ren PG, Avsian-Kretchmer O, et al. Obestatin, a peptide encoded by the ghrelin gene, opposes ghrelin’s effects on food
intake. Science. 2005;310(5750):996-9.
35. Ji B, Qu H, Wang H, Wei H, Deng H. Association Between the Visceral Adiposity Index and Homeostatic Model Assessment of Insulin Resistance in Participants With Normal Waist Circumference. Angiology. 2017;68(8):716-21.
36. Orces CH, Montalvan M, Tettamanti D. Prevalence of abdominal obesity and its association with cardiometabolic risk factors among older adults in Ecuador. Diabetes Metab Syndr. 2017;11(Suppl 2):S727-33.
37. Shen SW, Lu Y, Li F, et al. Atherogenic index of plasma is an effective index for estimating abdominal obesity. Lipids Health Dis. 2018;17(1):11.
38. Bertoli S, Leone A, Vignati L, et al. Metabolic correlates of subcutaneous and visceral abdominal fat measured by ultrasonography: A comparison with waist circumference. Nutr J. 2015;15(1):1-8.
39. Himmerich H, Fulda S, Linseisen J, et al. TNF-alpha, soluble TNF receptor and interleukin-6 plasma levels in the general population. Eur Cytokine Netw. 2006;17(3):196-201.
40. Cartier A, Lemieux I, Alméras N, et al. Visceral obesity and plasma glucose-insulin homeostasis: contributions of interleukin-6 and
tumor necrosis factor-alpha in men. J Clin Endocrinol Metab. 2008;93(5):1931-8.
41. Feitosa MC, Lima VB, Moita Neto JM, et al. Plasma concentration of IL-6 and TNF-α and its relationship with zincemia in obese women. Rev Assoc Med Bras. 2013;59(5):429-34.
42. Farhangi MA, Vajdi M, Fathollahi P. Dietary total antioxidant capacity, general and central obesity indices and serum lipids among adults: An updated systematic review and meta-analysis. Int J Vitam Nutr Res. 2022;92(5-6):406-22.
43. Zhang N, Yuan C, Li Z, et al. Meta-analysis of the relationship between obestatin and ghrelin levels and the ghrelin/obestatin ratio with respect to obesity. Am J Med Sci. 2011;341(1):48-55.
44. Hassouna R, Zizzari P, Tolle V. The ghrelin/obestatin balance in the physiological and pathological control of growth hormone secretion, body composition and food intake. J Neuroendocrinol. 2010;22(7):793-804.
45. Ibrahim AS, Eldeeb MM, Salama OA, et al. Possible association of ghrelin/obestatin balance with cardiometabolic risk in obese subjects with Helicobacter pylori. Endocr Regul. 2018;52(2):101-9.
46. Guo ZF, Zheng X, Qin YW, et al. Circulating preprandial ghrelin to obestatin ratio is increased in human obesity. J Clin Endocrinol
Metab. 2007;92(5):1875-80.
47. Deniz R, Gurates B, Aydin S, et al. Nesfatin-1 and other hormone alterations in polycystic ovary syndrome. Endocrine. 2012;42(3):694-9.
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2025 Esra Olgun, Birsen Aydin Kılıc, Sirin Cetin
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
